GLP-1 Medications Compared: Key Differences Explained

GLP-1 medications are the most significant development in weight management in decades. But "GLP-1" has become a catch-all term that obscures meaningful differences between the medications in this class. If you're considering a GLP-1 for weight loss, understanding what distinguishes one from another helps you have a better conversation with your physician.

What GLP-1 Medications Have in Common

All GLP-1 receptor agonists work by mimicking the GLP-1 hormone your body produces naturally. They activate receptors in the brain that regulate appetite and satiety, slow gastric emptying, and improve insulin sensitivity. The result is reduced hunger, increased fullness after meals, and — in clinical trials — meaningful, sustained weight loss.

Beyond that shared foundation, the differences matter.

Semaglutide

Semaglutide is the medication that put GLP-1s on the map for weight loss. Originally approved for type 2 diabetes, a higher-dose formulation was approved specifically for chronic weight management in 2021.

How it works: Pure GLP-1 receptor agonist. It activates GLP-1 receptors to reduce appetite and improve metabolic function.

Clinical results: In the STEP trials, participants lost an average of 14.9% of body weight over 68 weeks. Some participants lost significantly more.

Dosing: Once-weekly subcutaneous injection. Treatment typically starts at a low dose (0.25 mg) and titrates upward over 16-20 weeks to the maintenance dose.

Side effects: The most common are gastrointestinal — nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. These tend to diminish over time.

What makes it notable: Semaglutide has the most extensive weight-loss-specific clinical trial data and post-market experience. The SELECT trial also demonstrated a 20% reduction in major cardiovascular events, adding a significant benefit beyond weight loss alone.

Tirzepatide

Tirzepatide represents the next evolution — a dual-action medication that targets two hormone pathways instead of one.

How it works: Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP's role in weight management is still being fully understood, but the dual mechanism appears to produce additive benefits.

Clinical results: The SURMOUNT trials showed average weight loss of 20-22% of body weight at the highest doses — meaningfully more than semaglutide in head-to-head comparisons.

Dosing: Once-weekly subcutaneous injection, starting at 2.5 mg and titrating up over several months.

Side effects: Similar gastrointestinal profile to semaglutide. Some data suggests comparable or slightly higher rates of GI side effects during titration, though this varies by individual.

What makes it notable: Tirzepatide has produced the largest weight loss results of any GLP-1 class medication in clinical trials. It's particularly noteworthy for patients with type 2 diabetes, where its dual mechanism provides robust glycemic control alongside weight loss.

Liraglutide

Liraglutide was the first GLP-1 approved for weight management and has the longest track record.

How it works: Same GLP-1 receptor agonist mechanism as semaglutide, but with a shorter half-life requiring more frequent dosing.

Clinical results: Average weight loss of approximately 5-8% of body weight in clinical trials — effective but less than semaglutide or tirzepatide.

Dosing: Daily subcutaneous injection, which is the primary practical difference from the weekly dosing of newer options.

Side effects: Similar GI side effect profile. The daily dosing can be either a pro or a con depending on the patient — some prefer the consistency, others find it inconvenient.

What makes it notable: Liraglutide has the most long-term safety data due to its longer time on the market. It can be a reasonable option for patients who don't tolerate or respond well to semaglutide.

How to Think About the Differences

The practical considerations come down to a few factors:

Efficacy: Tirzepatide > Semaglutide > Liraglutide based on average weight loss in clinical trials. But individual responses vary. Some people respond dramatically to semaglutide and may not need the additional mechanism of tirzepatide.

Dosing convenience: Semaglutide and tirzepatide are both once weekly. Liraglutide is daily. For most people, weekly is preferable.

Tolerability: This is highly individual. Some patients tolerate one medication better than another. Starting low and titrating slowly helps with all three.

Cost and access: Availability and insurance coverage vary. Compounded formulations may be available for some of these medications, expanding access.

Your physician's assessment: The right medication depends on your complete health picture — metabolic status, comorbidities, other medications, and your specific treatment goals. This is why physician oversight matters.

The Bottom Line

These aren't interchangeable generic options. Each GLP-1 medication has a distinct profile. The best choice is the one that aligns with your clinical needs, your tolerance, and your physician's recommendation based on your individual health data.

[Learn more about our treatments](/treatments) or [start your intake today](/start).